{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:46:51Z","timestamp":1783399611341,"version":"3.54.6"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":131,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic urticaria (CU) is characterized by weals (hives) angio-oedema (or both) that last for \u2265 6 weeks, with chronic spontaneous urticaria (CSU) being the most common subtype. Patients with omalizumab-refractory CSU represent an unmet clinical need. In this study, we aimed to assess the prevalence and predictors of omalizumab failure in a large cohort of patients with CU and assess the effectiveness of dupilumab for omalizumab-refractory CU. Of 338 patients with CU, 33 received omalizumab; 69.7% (n = 23) were responders and 30.3% (n = 10) were nonresponders. Bivariate regression demonstrated that female sex [adjusted odds ratio (aOR) 1.53, 95% confidence interval (CI) 1.14\u20132.06], higher baseline weekly urticaria activity score (aOR 1.05, 95% CI 1.01\u20131.09) and older age (controlling for sex) (aOR 1.00, 95% CI 1.00\u20131.01) were associated with omalizumab failure. Of 10 patients with omalizumab-refractory CU, 3 were well controlled with ciclosporin (all children), whereas the 7 adults failed a mean [standard deviation (SD)] of 5.6 (2.6) treatments, including ciclosporin. All seven achieved a complete response with dupilumab, with time to response varying between 1 and 6 months. While our results suggest a favourable efficacy of dupilumab in patients with omalizumab-refractory CU, future confirmatory studies are required.<\/jats:p>","DOI":"10.1093\/ced\/llae145","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T22:08:54Z","timestamp":1715292534000},"page":"1227-1231","source":"Crossref","is-referenced-by-count":19,"title":["Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience"],"prefix":"10.1093","volume":"49","author":[{"given":"Catherine","family":"Zhu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessah","family":"BinJadeed","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofianne","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-220X","authenticated-orcid":false,"given":"Connor","family":"Prosty","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rahme","sequence":"additional","affiliation":[{"name":"Centre for Outcomes Research and Evaluation, McGill University Health Centre Research Institute , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Shand","sequence":"additional","affiliation":[{"name":"Centre for Outcomes Research and Evaluation, McGill University Health Centre Research Institute , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fein","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Ben-Shoshan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Netchiporouk","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2024091818150085000_llae145-B1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(23)02188-8","article-title":"Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria","volume":"403","author":"Moussa","year":"2024","journal-title":"Lancet"},{"key":"2024091818150085000_llae145-B2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"2024091818150085000_llae145-B3","doi-asserted-by":"crossref","first-page":"AB312","DOI":"10.1016\/j.jaci.2021.12.002","article-title":"Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID Study A)","volume":"149","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024091818150085000_llae145-B4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamadermatol.2017.3182","article-title":"Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria","volume":"153","author":"Netchiporouk","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024091818150085000_llae145-B5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jaad.2020.02.041","article-title":"Chronic urticaria in children can be controlled effectively with updosing second-\u00adgeneration antihistamines","volume":"82","author":"Gabrielli","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024091818150085000_llae145-B6","first-page":"3561","article-title":"Why a complete response is the treatment aim in chronic spontaneous urticaria","volume":"12","author":"Bernstein","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"2024091818150085000_llae145-B7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/pde.14360","article-title":"Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series","volume":"37","author":"Ari","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"2024091818150085000_llae145-B8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jaip.2021.03.034","article-title":"Managing chronic urticaria and recurrent angioedema differently with advancing age","volume":"9","author":"Longhurst","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024091818150085000_llae145-B9","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae145\/58600168\/llae145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1227\/59183581\/llae145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1227\/59183581\/llae145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T18:15:13Z","timestamp":1726683313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1227\/7667910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":9,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae145","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,10]]}}}